These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

373 related articles for article (PubMed ID: 33266405)

  • 1. Assessing the Effectiveness of Pirfenidone in Idiopathic Pulmonary Fibrosis: Long-Term, Real-World Data from European IPF Registry (eurIPFreg).
    Krauss E; Tello S; Wilhelm J; Schmidt J; Stoehr M; Seeger W; Dartsch RC; Crestani B; Guenther A
    J Clin Med; 2020 Nov; 9(11):. PubMed ID: 33266405
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Longitudinal clinical outcomes in a real-world population of patients with idiopathic pulmonary fibrosis: the PROOF registry.
    Wuyts WA; Dahlqvist C; Slabbynck H; Schlesser M; Gusbin N; Compere C; Maddens S; Lee YC; Kirchgaessler KU; Bartley K; Bondue B
    Respir Res; 2019 Oct; 20(1):231. PubMed ID: 31651324
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The European IPF registry (eurIPFreg): baseline characteristics and survival of patients with idiopathic pulmonary fibrosis.
    Guenther A; Krauss E; Tello S; Wagner J; Paul B; Kuhn S; Maurer O; Heinemann S; Costabel U; Barbero MAN; Müller V; Bonniaud P; Vancheri C; Wells A; Vasakova M; Pesci A; Sofia M; Klepetko W; Seeger W; Drakopanagiotakis F; Crestani B
    Respir Res; 2018 Jul; 19(1):141. PubMed ID: 30055613
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of Pirfenidone According to Dose in Patients with Idiopathic Pulmonary Fibrosis: A Prospective, Observational, Single-Center Cohort Study.
    Lee HY; Jung SY; Jang JH; Ko J; Kim DW; Her M; Lee JH
    Life (Basel); 2023 Oct; 13(11):. PubMed ID: 38004258
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pirfenidone in Idiopathic Pulmonary Fibrosis: Real-World Observation on Efficacy and Safety, Focus on Patients Undergoing Antithrombotic and Anticoagulant.
    Reccardini N; Chernovsky M; Salton F; Confalonieri P; Mondini L; Barbieri M; Romallo A; Maggisano M; Torregiani C; Geri P; Hughes M; Campochiaro C; Confalonieri M; Scarda A; Zuccon U; Ruaro B
    Pharmaceuticals (Basel); 2024 Jul; 17(7):. PubMed ID: 39065780
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and Safety of Pirfenidone in Advanced Versus Non-Advanced Idiopathic Pulmonary Fibrosis: Post-Hoc Analysis of Six Clinical Studies.
    Behr J; Nathan SD; Costabel U; Albera C; Wuyts WA; Glassberg MK; Haller H; Alvaro G; Gilberg F; Samara K; Lancaster L
    Adv Ther; 2023 Sep; 40(9):3937-3955. PubMed ID: 37391667
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Impact of Autoantibodies on Outcomes in Patients with Idiopathic Pulmonary Fibrosis: Post-Hoc Analyses of the Phase III ASCEND Trial.
    Kulkarni T; Newton CA; Gupta S; Samara K; Bernstein EJ
    Pulm Ther; 2024 Sep; 10(3):331-346. PubMed ID: 39073523
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Effectiveness, Safety, and Tolerability of Pirfenidone in Idiopathic Pulmonary Fibrosis: A Retrospective Study.
    Hanta I; Cilli A; Sevinc C
    Adv Ther; 2019 May; 36(5):1126-1131. PubMed ID: 30900199
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of pirfenidone in the management of pulmonary fibrosis.
    Meyer KC; Decker CA
    Ther Clin Risk Manag; 2017; 13():427-437. PubMed ID: 28435277
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical and Functional Characteristics of Patients with Unclassifiable Interstitial Lung Disease (uILD): Long-Term Follow-Up Data from European IPF Registry (eurIPFreg).
    Krauss E; El-Guelai M; Pons-Kuehnemann J; Dartsch RC; Tello S; Korfei M; Mahavadi P; Breithecker A; Fink L; Stoehr M; Majeed RW; Seeger W; Crestani B; Guenther A
    J Clin Med; 2020 Aug; 9(8):. PubMed ID: 32756496
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-life comparison of pirfenidone and nintedanib in patients with idiopathic pulmonary fibrosis: A 24-month assessment.
    Cerri S; Monari M; Guerrieri A; Donatelli P; Bassi I; Garuti M; Luppi F; Betti S; Bandelli G; Carpano M; Bacchi Reggiani ML; Tonelli R; Clini E; Nava S
    Respir Med; 2019 Nov; 159():105803. PubMed ID: 31670147
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and efficacy of pirfenidone in idiopathic pulmonary fibrosis in clinical practice.
    Okuda R; Hagiwara E; Baba T; Kitamura H; Kato T; Ogura T
    Respir Med; 2013 Sep; 107(9):1431-7. PubMed ID: 23849626
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictive factors for the long-term use of pirfenidone in patients with fibrosing interstitial lung disease.
    Katano T; Sekine A; Ikeda S; Yamakawa H; Misumi T; Okabayashi H; Okuda R; Kitamura H; Baba T; Komatsu S; Hagiwara E; Ogura T
    Respir Investig; 2021 Jul; 59(4):414-420. PubMed ID: 33618993
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Deterioration of high-resolution computed tomography findings predicts disease progression after initial decline in forced vital capacity in idiopathic pulmonary fibrosis patients treated with pirfenidone.
    Higo H; Miyahara N; Taniguchi A; Senoo S; Itano J; Watanabe H; Oda N; Kayatani H; Ichikawa H; Shibayama T; Kajimoto K; Tanimoto Y; Kanehiro A; Maeda Y; Kiura K;
    Respir Investig; 2020 May; 58(3):185-189. PubMed ID: 32102769
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness of combined therapy with pirfenidone and inhaled N-acetylcysteine for advanced idiopathic pulmonary fibrosis: a case-control study.
    Sakamoto S; Muramatsu Y; Satoh K; Ishida F; Kikuchi N; Sano G; Sugino K; Isobe K; Takai Y; Homma S
    Respirology; 2015 Apr; 20(3):445-52. PubMed ID: 25639750
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of pirfenidone for idiopathic pulmonary fibrosis: An Italian real life study.
    Harari S; Caminati A; Albera C; Vancheri C; Poletti V; Pesci A; Luppi F; Saltini C; Agostini C; Bargagli E; Sebastiani A; Sanduzzi A; Giunta V; Della Porta R; Bandelli GP; Puglisi S; Tomassetti S; Biffi A; Cerri S; Mari A; Cinetto F; Tirelli F; Farinelli G; Bocchino M; Specchia C; Confalonieri M
    Respir Med; 2015 Jul; 109(7):904-13. PubMed ID: 25962649
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A 2-Year Observational Study in Patients Suffering from Idiopathic Pulmonary Fibrosis and Treated with Pirfenidone: A French Ancillary Study of PASSPORT.
    Jouneau S; Gamez AS; Traclet J; Nunes H; Marchand-Adam S; Kessler R; Israël-Biet D; Borie R; Strombom I; Scalori A; Crestani B; Valeyre D; Cottin V
    Respiration; 2019; 98(1):19-28. PubMed ID: 30965332
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical characteristics of patients with familial idiopathic pulmonary fibrosis (f-IPF).
    Krauss E; Gehrken G; Drakopanagiotakis F; Tello S; Dartsch RC; Maurer O; Windhorst A; von der Beck D; Griese M; Seeger W; Guenther A
    BMC Pulm Med; 2019 Jul; 19(1):130. PubMed ID: 31319833
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Composite Physiologic Index, Percent Forced Vital Capacity and Percent Diffusing Capacity for Carbon Monoxide Could Be Predictors of Pirfenidone Tolerability in Patients with Idiopathic Pulmonary Fibrosis.
    Konishi S; Arita M; Ito I; Tachibana H; Takaiwa T; Fukuda Y; Watanabe N; Tsubouchi K; Masuda G; Tanaka M; Kourogi Y; Kunimasa K; Nishiyama A; Iwasaku M; Ito A; Tokioka F; Yoshioka H; Hashimoto T; Ishida T
    Intern Med; 2015; 54(22):2835-41. PubMed ID: 26567995
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pirfenidone treatment in idiopathic pulmonary fibrosis: A Saudi experience.
    Alhamad EH
    Ann Thorac Med; 2015; 10(1):38-43. PubMed ID: 25593606
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.